Silexion Therapeutics Corp
SLXN·NasdaqCM·Healthcare
0.1782−0.0364 (−16.96%)today
At close: Oct 12, 4:00 PM EDT · May be delayed up to 15 min · USD
After hours0.1800+0.0018 (+1.01%)Oct 12, 7:50 PM EDT
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Previous close0.2146
Open0.2082
Day range0.17660.2082
52-week range0.176639.4000
Off day high−14.41%
Off 52-week high−99.55%
Volume1.22M
Avg. volume (3M)9.91M
Market cap2.58M
EPS (TTM)-27.21
Forward P/E-0.28
P/E ratio (TTM)—
Dividend yield—
Beta (5Y)-0.30
Shares outstanding14.47M
Short interest34.47% of float
Earnings dateAug 7, 2025 (est.)
Analyst target5.0000
Profit margin0.00%
Against its peers
Compare in full ›| SLXN | GNPX | BDRX | PCSA | RNAZ | XBIO | |
|---|---|---|---|---|---|---|
| Market cap | 2.58M | 2.21M | 844.66K | 5.31M | 27.60M | 4.97M |
| P/E (TTM) | — | — | 0.0 | — | — | — |
| Forward P/E | -0.3 | -1.2 | — | -0.5 | -2.7 | -3.2 |
| Price/book | 22.3 | 0.1 | 0.0 | -16.7 | -0.1 | 0.8 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −99.42% | −98.74% | −99.09% | −86.21% | −86.24% | −60.34% |
| Today | −16.96% | −1.10% | −16.73% | +25.00% | −12.37% | −0.47% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All SLXN news ›Silexion Therapeutics Corp Ord Stock Short Interest Rises to 91.58%
Silexion Therapeutics Corp Ord short interest was 91.58% of the float on September 30th, according to new data we received from Benzinga. Short interest totaled 4,925,958 shares, which was an increase of 1,964.38% from September 15th.It is…
From articles in the 4Search news index.
In the news
2mentions in 30 days
2with it in the headline
Negativesentiment
Mentioned with
People in the coverage
Most coverage from
-
kalkinemedia.com1
-
quiverquant.com1
Finance and business coverage in the 4Conservative news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 2 articles, not a forecast.